Logo image of ALGEN.PA

GENOWAY SA (ALGEN.PA) Stock Price, Forecast & Analysis

Europe - EPA:ALGEN - FR0004053510 - Common Stock

2.48 EUR
+0.01 (+0.4%)
Last: 11/7/2025, 7:00:00 PM

ALGEN.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap23.51M
Revenue(TTM)22.06M
Net Income(TTM)1.26M
Shares9.48M
Float6.72M
52 Week High4.1
52 Week Low2.4
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.21
PE11.81
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2007-05-04
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ALGEN.PA short term performance overview.The bars show the price performance of ALGEN.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

ALGEN.PA long term performance overview.The bars show the price performance of ALGEN.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of ALGEN.PA is 2.48 EUR. In the past month the price decreased by -15.93%. In the past year, price decreased by -28.32%.

GENOWAY SA / ALGEN Daily stock chart

ALGEN.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ARGX.BR ARGENX SE69.3245.88B
1AE.DE ARGENX SE67.9144.95B
22UA.DE BIONTECH SE-ADRN/A21.86B
2X1.DE ABIVAX SAN/A6.90B
ABVX.PA ABIVAX SAN/A7.11B
GLPG.AS GALAPAGOS NVN/A1.84B
5CV.DE CUREVAC NV5.171.01B
NANO.PA NANOBIOTIXN/A929.59M
PHIL.MI PHILOGEN SPA21.14704.68M
IVA.PA INVENTIVA SAN/A483.52M
FYB.DE FORMYCON AGN/A360.47M
VLA.PA VALNEVA SEN/A321.33M

About ALGEN.PA

Company Profile

ALGEN logo image genOway SA engages in the development of genetically modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 143 full-time employees. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.

Company Info

GENOWAY SA

Technopark 2, 31 Rue Saint Jean-de-Dieu

Lyon AUVERGNE-RHONE-ALPES FR

Employees: 128

ALGEN Company Website

ALGEN Investor Relations

Phone: 33437654100

GENOWAY SA / ALGEN.PA FAQ

Can you describe the business of GENOWAY SA?

genOway SA engages in the development of genetically modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 143 full-time employees. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.


Can you provide the latest stock price for GENOWAY SA?

The current stock price of ALGEN.PA is 2.48 EUR. The price increased by 0.4% in the last trading session.


Does GENOWAY SA pay dividends?

ALGEN.PA does not pay a dividend.


How is the ChartMill rating for GENOWAY SA?

ALGEN.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Can you provide the number of employees for GENOWAY SA?

GENOWAY SA (ALGEN.PA) currently has 128 employees.


ALGEN.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALGEN.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to ALGEN.PA. ALGEN.PA scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALGEN.PA Financial Highlights

Over the last trailing twelve months ALGEN.PA reported a non-GAAP Earnings per Share(EPS) of 0.21. The EPS increased by 18.41% compared to the year before.


Industry RankSector Rank
PM (TTM) 5.86%
ROA 3.96%
ROE 7.06%
Debt/Equity 0.26
Chartmill High Growth Momentum
EPS Q2Q%108%
Sales Q2Q%5.92%
EPS 1Y (TTM)18.41%
Revenue 1Y (TTM)10.04%

ALGEN.PA Forecast & Estimates

9 analysts have analysed ALGEN.PA and the average price target is 6.02 EUR. This implies a price increase of 142.66% is expected in the next year compared to the current price of 2.48.

For the next year, analysts expect an EPS growth of -100% and a revenue growth -7.14% for ALGEN.PA


Analysts
Analysts86.67
Price Target6.02 (142.74%)
EPS Next Y-100%
Revenue Next Year-7.14%

ALGEN.PA Ownership

Ownership
Inst Owners5.68%
Ins Owners10.39%
Short Float %N/A
Short RatioN/A